Elicio Therapeutics, Inc.
ELTX
$10.60
-$0.43-3.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.82% | -5.32% | -4.77% | 14.18% | 52.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.03% | 19.12% | 25.85% | 26.57% | 51.31% |
| Operating Income | -8.03% | -19.12% | -25.85% | -26.57% | -51.31% |
| Income Before Tax | -41.25% | -31.51% | -47.46% | -42.39% | -31.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.25% | -31.51% | -47.46% | -42.39% | -31.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.25% | -31.51% | -47.46% | -42.39% | -31.34% |
| EBIT | -8.03% | -19.12% | -25.85% | -26.57% | -51.31% |
| EBITDA | -8.25% | -19.46% | -26.30% | -27.18% | -52.44% |
| EPS Basic | 4.28% | 35.58% | 85.85% | 91.45% | 94.19% |
| Normalized Basic EPS | 3.65% | 37.72% | 85.94% | 91.46% | 94.21% |
| EPS Diluted | 4.28% | 35.58% | 85.85% | 91.45% | 94.19% |
| Normalized Diluted EPS | 3.65% | 37.72% | 85.94% | 91.46% | 94.21% |
| Average Basic Shares Outstanding | 46.17% | 71.07% | 142.30% | 266.67% | 898.16% |
| Average Diluted Shares Outstanding | 46.17% | 71.07% | 142.30% | 266.67% | 898.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |